High doses of IL-2 are required to sustain the growth and proliferation of PBMC-derived tumour-reactive T cells and of clonal tumour infiltrating lymphocytes that were expanded ex vivo, after their reinfusion (Rosenberg et al, 1988; Dudley et al, 2002). The gene discussed is IL2; the disease is neoplasm.